FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317746143> ?p ?o ?g. }

• W4317746143 abstract "Abstract Background Dysthyroid optic neuropathy (DON) is a serious threatening vision loss in Graves’ ophthalmopathy (GO). Although the European Group on Graves’ Ophthalmopathy (EUGOGO) recommend intravenous methylprednisolone therapy for first line treatment, some characteristics predicting the response are still inconclusive. Aim To study the efficacy of intravenous pulse methylprednisolone (IVMP) in treating dysthyroid optic neuropathy (DON) and to identify factors predicting poor response to the treatment. Methods All patients diagnosed with DON between January 2010 and December 2021 at Rajavithi Hospital, Thailand, receiving IVMP 1 g/ day for 3 consecutive days were analyzed. The efficacy at 1 week and 3, 6, 12-months in terms of improvement of best corrected visual acuity (BCVA) and proptosis were compiled. Results Of the entire 57 DON cases that received IVMP, 50.9% gained at least 0.2 Logarithm of the Minimum Angle of Resolution (logMAR) at 1 week, and the improvement from initial to 1-week BCVA was 0.63 ± 0.63 logMAR ( p < 0.001) and the decrease in proptosis was 1.8 ± 1.36 mm ( p < 0.001). The remaining 23 orbits underwent orbital decompression and were excluded from the long-term efficacy analysis. In the last 12-months’ follow-up time, there was an improvement of BCVA (0.53 ± 0.47 logMAR) and proptosis (0.59 ± 0.66 mm) (both p < 0.001). At last visit, there was an improvement of BCVA (0.2 logMAR) and proptosis (2 mm) in 76.5, and 5.9% respectively. Significant predictive factors of poor treatment response were age ≥ 55 years (odds ratio [OR]: 8.28, 95% confidence interval [CI]: 1.368–50.121, p = 0.021); longer onset duration before treatment (OR: 5.10, 95%CI: 1.061–24.501, p = 0.042); and proptosis at baseline (OR: 9.31, 95%CI: 1.872–46.280, p = 0.006). The strongest risk factor for predicting poor response to IVMP was poor initial visual acuity (OR: 10.26, 95%CI: 1.363–77.234, p = 0.024). Conclusions IVMP is effective for both short- and long-term treatment to improve visual acuity greater than proptosis. Older age, longer disease duration, poor initial visual acuity, and proptotic orbits were identified as risk factors for predicting poor response to IVMP treatment in Thai population. DON patients having those risk factors should be suspected, and treated early with IVMP to preserve their future vision." @default.
• W4317746143 created "2023-01-23" @default.
• W4317746143 creator A5006710956 @default.
• W4317746143 creator A5016453277 @default.
• W4317746143 creator A5032028791 @default.
• W4317746143 date "2023-01-23" @default.
• W4317746143 modified "2023-10-18" @default.
• W4317746143 title "A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy" @default.
• W4317746143 cites W146930876 @default.
• W4317746143 cites W1607460457 @default.
• W4317746143 cites W1982609434 @default.
• W4317746143 cites W1986420001 @default.
• W4317746143 cites W2000612896 @default.
• W4317746143 cites W2000837142 @default.
• W4317746143 cites W2017353779 @default.
• W4317746143 cites W2021192826 @default.
• W4317746143 cites W2038106393 @default.
• W4317746143 cites W2046586151 @default.
• W4317746143 cites W2050700872 @default.
• W4317746143 cites W2052463348 @default.
• W4317746143 cites W2052697772 @default.
• W4317746143 cites W2054171287 @default.
• W4317746143 cites W2055167616 @default.
• W4317746143 cites W2060748271 @default.
• W4317746143 cites W2074776983 @default.
• W4317746143 cites W2079247170 @default.
• W4317746143 cites W2081212738 @default.
• W4317746143 cites W2082941359 @default.
• W4317746143 cites W2084079316 @default.
• W4317746143 cites W2084145883 @default.
• W4317746143 cites W2085551462 @default.
• W4317746143 cites W2107874980 @default.
• W4317746143 cites W2112122807 @default.
• W4317746143 cites W2112957774 @default.
• W4317746143 cites W2144470478 @default.
• W4317746143 cites W2168889372 @default.
• W4317746143 cites W2276509781 @default.
• W4317746143 cites W2288910126 @default.
• W4317746143 cites W2326911230 @default.
• W4317746143 cites W2332315196 @default.
• W4317746143 cites W2400708399 @default.
• W4317746143 cites W2411038331 @default.
• W4317746143 cites W2412145990 @default.
• W4317746143 cites W2794967904 @default.
• W4317746143 cites W2808866108 @default.
• W4317746143 cites W3005428370 @default.
• W4317746143 cites W3021272691 @default.
• W4317746143 cites W3029858388 @default.
• W4317746143 cites W3045586899 @default.
• W4317746143 cites W3093294661 @default.
• W4317746143 cites W3107470055 @default.
• W4317746143 cites W3186410608 @default.
• W4317746143 cites W4240137178 @default.
• W4317746143 doi "https://doi.org/10.1186/s12886-023-02789-5" @default.
• W4317746143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36690985" @default.
• W4317746143 hasPublicationYear "2023" @default.
• W4317746143 type Work @default.
• W4317746143 citedByCount "1" @default.
• W4317746143 countsByYear W43177461432023 @default.
• W4317746143 crossrefType "journal-article" @default.
• W4317746143 hasAuthorship W4317746143A5006710956 @default.
• W4317746143 hasAuthorship W4317746143A5016453277 @default.
• W4317746143 hasAuthorship W4317746143A5032028791 @default.
• W4317746143 hasBestOaLocation W43177461431 @default.
• W4317746143 hasConcept C118487528 @default.
• W4317746143 hasConcept C126322002 @default.
• W4317746143 hasConcept C141071460 @default.
• W4317746143 hasConcept C2776652619 @default.
• W4317746143 hasConcept C2776685619 @default.
• W4317746143 hasConcept C2778233873 @default.
• W4317746143 hasConcept C2778257484 @default.
• W4317746143 hasConcept C2780372218 @default.
• W4317746143 hasConcept C2780837183 @default.
• W4317746143 hasConcept C526584372 @default.
• W4317746143 hasConcept C71924100 @default.
• W4317746143 hasConceptScore W4317746143C118487528 @default.
• W4317746143 hasConceptScore W4317746143C126322002 @default.
• W4317746143 hasConceptScore W4317746143C141071460 @default.
• W4317746143 hasConceptScore W4317746143C2776652619 @default.
• W4317746143 hasConceptScore W4317746143C2776685619 @default.
• W4317746143 hasConceptScore W4317746143C2778233873 @default.
• W4317746143 hasConceptScore W4317746143C2778257484 @default.
• W4317746143 hasConceptScore W4317746143C2780372218 @default.
• W4317746143 hasConceptScore W4317746143C2780837183 @default.
• W4317746143 hasConceptScore W4317746143C526584372 @default.
• W4317746143 hasConceptScore W4317746143C71924100 @default.
• W4317746143 hasIssue "1" @default.
• W4317746143 hasLocation W43177461431 @default.
• W4317746143 hasLocation W43177461432 @default.
• W4317746143 hasLocation W43177461433 @default.
• W4317746143 hasLocation W43177461434 @default.
• W4317746143 hasOpenAccess W4317746143 @default.
• W4317746143 hasPrimaryLocation W43177461431 @default.
• W4317746143 hasRelatedWork W2112122807 @default.
• W4317746143 hasRelatedWork W2137999350 @default.
• W4317746143 hasRelatedWork W2180895180 @default.
• W4317746143 hasRelatedWork W2187674700 @default.
• W4317746143 hasRelatedWork W2347739965 @default.
• W4317746143 hasRelatedWork W2393920701 @default.
• W4317746143 hasRelatedWork W2410986393 @default.

• next